CRBP
CRBP
NASDAQ · Biotechnology

Corbus Pharmaceuticals Holdi

$10.25
+0.86 (+9.16%)
As of Apr 1, 2:55 PM ET ·
Financial Highlights (FY 2025)
Revenue
72.40M
Net Income
-2,537,554
Gross Margin
57.9%
Profit Margin
-3.5%
Rev Growth
+4.2%
D/E Ratio
0.37
Revenue & Net Income
Margin Trends
FY 2025 FY 2024 FY 2023
Gross Margin 57.9% 57.9% 57.9%
Operating Margin -3.9% -4.3% -4.9%
Profit Margin -3.5% -3.7% -4.9%
Income Statement
FY 2025 FY 2024 FY 2023
Revenue 72.40M 73.75M 70.02M
Gross Profit 41.90M 42.68M 40.53M
Operating Income -2,795,245 -3,177,201 -3,400,402
Net Income -2,537,554 -2,715,843 -3,439,667
Gross Margin 57.9% 57.9% 57.9%
Operating Margin -3.9% -4.3% -4.9%
Profit Margin -3.5% -3.7% -4.9%
Rev Growth +4.2% -7.8% -7.0%
Balance Sheet
FY 2025 FY 2024 FY 2023
Total Debt 33.68M 30.99M 34.49M
Total Equity 90.51M 100.10M 94.61M
D/E Ratio 0.37 0.31 0.36
Cash Flow
FY 2025 FY 2024 FY 2023
EBITDA -3,891,696 -4,515,140 -4,413,459
Free Cash Flow -4,239,895 -2,837,667 -3,192,005